Case Report

High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis

Toshihide Yoshikawa,1 Akihiko Tanizawa,1,2 Koji Suzuki,1 Kazumi Ikeda,1 Eishi Nomura,1 Yumekichi Maeda,1,3 Nanae Tanaka,1,3 Kenta Yamada,1 Yasuhiro Sakai,4 Yoshiaki Imamura,5 and Yusei Ohshima1

1Department of Pediatrics, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
2Department of Human Resource Development for Cancer, Faculty of Medical Sciences, University of Fukui, 23-3 Matsu-oka-shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
3Department of Pediatrics, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui 918-8011, Japan
4Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan
5Division of Surgical Pathology, University of Fukui Hospital, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan

Correspondence should be addressed to Toshihide Yoshikawa; ytoshi@u-fukui.ac.jp

Received 25 January 2017; Revised 28 February 2017; Accepted 21 March 2017; Published 30 March 2017

Renal metastasis at diagnosis with neuroblastoma is extremely rare. The published incidences ranged from 0% (none of 567 cases) [1] to 0.7% (1 of 153 cases) [2] in stage 4 patients (excluding stage 4S patients), whereas the incidences at other sites were 75.7% in bone marrow, 63.7% in bone, 34.0% in lymph node, 22.4% in liver, and 20.8% in intracranial and orbital sites [1]. Since few case reports of neuroblastoma with renal metastasis have been published [3, 4] and, to the best of our knowledge, there are no reports in the English medical literature of neuroblastoma with bilateral renal metastases at diagnosis, the significance of the condition for prognosis remains unknown. In the setting of bilateral and multiple renal metastases, local therapeutic modalities for the kidneys, such as nephrectomy and/or radiotherapy, cannot be considered because the patient will completely lose renal function. Here, we present the clinical course of a patient with stage 4 neuroblastoma who had multiple metastatic lesions in bilateral kidneys at diagnosis.

1. Introduction

Renal metastasis at diagnosis with neuroblastoma is extremely rare. The published incidences ranged from 0% (none of 567 cases) [1] to 0.7% (1 of 153 cases) [2] in stage 4 patients (excluding stage 4S cases), whereas the incidences at other sites were 75.7% in bone marrow, 63.7% in bone, 34.0% in lymph node, 22.4% in liver, and 20.8% in intracranial and orbital sites [1]. Since few case reports of neuroblastoma with renal metastasis have been published [3, 4] and, to the best of our knowledge, there are no reports in the English medical literature of neuroblastoma with bilateral renal metastases at diagnosis, the significance of the condition for prognosis remains unknown. In the setting of bilateral and multiple renal metastases, local therapeutic modalities for the kidneys, such as nephrectomy and/or radiotherapy, cannot be considered because the patient will completely lose renal function. Here, we present the clinical course of a patient with stage 4 neuroblastoma who had multiple metastatic lesions in bilateral kidneys at diagnosis.
2. Case Presentation

A 14-month-old boy with a large abdominal mass was admitted to our hospital. Serum neuron-specific enolase (NSE) was markedly elevated (1,000 ng/mL), while urinary homovanillic and vanillylmandelic acid were within the normal range. Magnetic resonance imaging (MRI) and computerized tomography revealed a left adrenal mass with calcification and metastases to cranial bones, cranial base, bilateral orbits, left pleura, thoracic paravertebral soft tissue, para-aortic lymph nodes, soft tissue in the sacral canal, and bilateral kidneys (Figures 1(a), 1(c), and 1(e)). However, blood and urine tests indicated no impairment of renal function. Uptake of iodine-123-metaiodobenzylguanidine ($^{123}$I-MIBG) was heterogeneous, being highly increased in cranial bones, cranial base, and bilateral orbits but only slightly increased in the primary lesion and bilateral kidneys and weak in other sites. Biopsy of the adrenal tumor was
Table 1: Details of chemotherapy and CBT.

| Induction chemotherapy | HDC with auto-PBSCT | Cord blood transplantation |
|-------------------------|---------------------|--------------------------|
| **Cyclophosphamide**    | **Melphalan**       | **Conditioning regimen** |
| 1,200 mg/m²/day on days 1 and 2, except for day 2 in cycle 1 | 100 mg/m²/day on days -9 and -8 | **Fludarabine** |
| **Vincristine**         | **Etoposide**       | 25 mg/m²/day on days -7 to -3 |
| 1.5 mg/m² on day 1     | 200 mg/m²/day on days -7 to -4 |
| **Pirarubicin**         | **Carboplatin**     | 70 mg/m³/day on days -4 and -3 |
| 40 mg/m² on day 3      | 2 Gy on day -2      |
| **Cisplatin**           |                    | **GVHD prophylaxis**     |
| 20 mg/m²/day continuously from days 1 to 5       | Tacrolimus and short-term methotrexate |

| HLA typing | A         | B          | C           | DRBI    |
|------------|-----------|------------|-------------|---------|
| **Recipient** | 24:02/*—* | 51:01/52:01 | 12:02/14:02 | 04:05/15:02 |
| **Donor**   | 24:02/*—* | 51:01/52:01 | 12:02/15:02 | 15:02/*—* |

CBT: cord blood cell transplantation; HDC: high-dose chemotherapy; auto-PBSCT: autologous peripheral blood stem cell transplantation; TBI: total body irradiation; GVHD: graft-versus-host disease; HLA: human leukocyte antigen.

performed, and a diagnosis of poorly differentiated neuroblastoma with low mitosis-karyorrhexis index was confirmed. NSE immunohistochemistry was partially positive. Overall, histology was favorable based on International Neuroblastoma Pathology Classification; however, fluorescence in situ hybridization showed that tumor cells with and without amplification of the MYCN oncogene coexisted in the biopsied specimen. Bone marrow examination showed tumor cells with a highly amplified MYCN oncogene. The patient was diagnosed as high-risk according to the International Neuroblastoma Risk Group Classification System.

The patient received five cycles of induction chemotherapy, high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (auto-PBSCT), followed by surgical resection of the primary tumor together with renal biopsy, and finally cranial irradiation (Table 1). Although all of the lesions shrunk and serum NSE decreased to within the normal range, there were still residual masses in the primary site, left orbit, sacral canal, and bilateral kidneys after five courses of induction chemotherapy (Figures 1(b), 1(d), and 1(f)). The sizes of residual masses in the primary lesion, sacral canal, and bilateral kidneys were slightly reduced by HDC. Histological examination of the resected primary tumor and a biopsy specimen obtained from the left kidney were positive for synaptophysin, chromogranin A, and cluster of differentiation (CD) 56 but not NSE, confirming the presence of tumor cells (Figures 2(a)–2(h)). These findings supposed that some tumor cells also remained in the opposite renal metastatic nodules, which were depicted in the same manner on MRI. We chose the graft-versus-tumor (GVT) approach with allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a potentially curative treatment to avoid bilateral nephrectomy or local radiotherapy to both kidneys. The patient underwent unrelated cord blood stem cell transplantation (CBT) from a human leukocyte antigen- (HLA-) C and DRBI mismatched donor at four months after auto-PBSCT (Table 1). In addition, the HLA-C mismatch between the donor and the recipient induced killer cell immunoglobulin-like receptor- (KIR-) ligand incompatibility in the graft-versus-host direction to generate natural killer (NK) cell alloreactivity against neuroblastoma cells. The conditioning regimen consisted of fludarabine, melphalan, and total body irradiation (TBI), and tacrolimus with short-term methotrexate was administrated for graft-versus-host disease (GVHD) prophylaxis (Table 1). Radiotherapy to the primary tumor bed and sacrum was planned. However, the residual mass in the sacral canal was enlarged and a new metastatic lesion appeared in the pancreatic tail at three months after CBT. Tumor progression could not be controlled by additional chemotherapy and local radiotherapy, and the patient succumbed at 26 months after diagnosis and 12 months after relapse. There was no recurrence in cranial bones where 19.8 Gy of local radiotherapy was delivered between HDC and CBT. Furthermore, the metastatic nodules in bilateral kidneys did not increase in size before his death and there was no evidence of GVHD. We could not examine the histopathological status of the renal involvements because autopsy was not performed.

3. Discussion

Multidisciplinary treatment has improved therapeutic efficiency for high-risk neuroblastoma [5, 6]. However, the prognosis for patients with renal metastasis at diagnosis is unclear, since kidney is a rare metastatic site [1, 2]. When the sites of renal metastases were unilateral, surgical resection or
Figure 2: Histological findings of the primary tumor and a residual mass in the left kidney. In the primary tumor, H&E staining demonstrated neuroblastoma cell clusters (a), and these cells were immunohistochemically positive for (c) synaptophysin, (e) chromogranin A, and (g) CD56. In the left kidney, it was difficult to identify the metastatic lesion due to chemotherapy (b); however, immunohistochemistry revealed the individually scattered neuroblastoma cells (d–h). Note that color reaction was performed using new fuchsin (red), and brown pigments were hemosiderin or ceroid.
radiotherapy for the involved kidney is an attractive option, whereas both modalities could not be considered in our case with bilateral and multiple renal metastatic lesions.

In the 2000s, allo-HSCT was reported to induce a GVT effect against neuroblastoma [7–9]. Moreover, lacking an HLA ligand for inhibitory KIR was reported to be associated with low risk of disease progression, even in patients who had undergone autologous HSCT for high-risk neuroblastoma [10]. Therefore, allogeneic immunity and NK cell alloreactivity in the graft–versus-host direction to tumor cells were also expected in our case (Table 1). In this case, although new and recurrent lesions were detected in multiple sites within three months of CBT, the renal lesions did not progress. CD56 and perforin expression distinguishes two subsets of human NK cells: CD56dim perforinhigh (cytotoxic) and CD56bright perforinlow (noncytotoxic). Carrega et al. reported that the frequencies of total NK cells among lymphocytes and CD56dim perforinhigh NK cells among total NK cells were higher in kidney than in lymph node and stomach [11]. Thus, cytotoxic NK cells may be particularly abundant in the kidney. Furthermore, biological characteristics, including sensitivity to chemotherapy, might be lesion dependent because NSE immunohistochemistry in the primary lesion, uptake of 123I-MIBG in the primary lesion and metastatic sites, and MYCN amplification in the primary lesion and bone marrow aspirate were heterogeneous, and there was a higher residual tumor burden in the primary lesion compared with the renal lesion after auto-PBSC (Figures 2(a)–2(h)). Thus, the distribution of NK cells and the biological characteristics of neuroblastoma cells in the renal lesion might contribute to a favorable therapeutic response.

In summary, to the best of our knowledge, this is the first case report of neuroblastoma with bilateral renal metastases at diagnosis in the English medical literature. No clinical progression of the renal lesions occurred during multidisciplinary treatment. Although the patient eventually died, our report suggests that the combination of chemotherapy and immunotherapy may prevent the progression of renal lesions under certain conditions, since 2 Gy of TBI at CBT is not usually enough to control neuroblastoma progression. This case shows the possibility that chemotherapy and immunotherapy might be therapeutic options against neuroblastoma with bilateral renal involvement to preserve renal function, if the primary tumor and other metastatic involvements could be controllable with multidisciplinary treatment including surgical interventions.

Conduct

Informed consent was obtained from the patient’s parents for publication.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

The authors would like to thank Yoshiyuki Takahashi, M.D., Ph.D., Department of Pediatrics/Developmental Pediatrics, Nagoya University Graduate School of Medicine, for advice in regard to CBT.

References

[1] S. G. DuBois, Y. Kalika, J. N. Lukens et al., “Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival,” Journal of Pediatric Hematology/Oncology, vol. 21, no. 3, pp. 181–189, 1999.
[2] M. A. Escobar, J. L. Grosfeld, R. L. Powell et al., “Long-term outcomes in patients with stage IV neuroblastoma,” Journal of Pediatric Surgery, vol. 41, no. 2, pp. 377–381, 2006.
[3] D. Filiatrault, C. Hoyoux, P. Benoît, L. Garel, and D. Esseltine, “Renal metastases from neuroblastoma—report of two cases,” Pediatric Radiology, vol. 17, no. 2, pp. 137–138, 1987.
[4] H. J. Sul and D. Y. Kang, “Congenital neuroblastoma with multiple metastases: a case report,” Journal of Korean Medical Science, vol. 18, no. 4, pp. 618–620, 2003.
[5] K. K. Matthey, C. P. Reynolds, R. C. Seeger et al., “Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1007–1013, 2009.
[6] A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., “Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1324–1334, 2010.
[7] M. Inoue, T. Nakano, A. Yoneda et al., “Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation,” Bone Marrow Transplantation, vol. 32, no. 1, pp. 103–106, 2003.
[8] A. Marabelle, C. Paillard, A. Tchirkov et al., “Graft-versus-tumor effect in refractory metastatic neuroblastoma,” Bone Marrow Transplantation, vol. 39, no. 12, pp. 809–810, 2007.
[9] K. Goi, T. Inukai, H. Honna et al., “Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN,” Bone Marrow Transplantation, vol. 46, no. 6, pp. 835–839, 2011.
[10] J. M. Venstrom, J. Zheng, N. Noor et al., “KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma,” Clinical Cancer Research, vol. 15, no. 23, pp. 7330–7334, 2009.
[11] P. Carrega, I. Bonaccorsi, E. Di Carlo et al., “CD56bright perforinlow noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph,” Journal of Immunology, vol. 192, no. 8, pp. 3805–3815, 2014.